Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- State laws may be curbing private equity takeovers of physician group (STAT)
- AI Shows Promise Across Spectrum of GI Motility Diagnostics, Review Finds (GI & Endoscopy News)
- Simple mouth rinse may help detect stomach and colorectal cancer signals (Medical Xpress)
- Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs (MedCity News)
- Top AI in Endoscopy Companies Revolutionizing Real-Time Diagnostics and Intelligent Endoscopic Care (Fortune Business Insights)
- Rome V criteria capture more people with IBS, but a milder group (GI & Hepatology News)
- Real-World IBS Study Links IBS-Smart® and Trio-Smart® Testing to Lower Use of Selected Diagnostic Procedures and Lower Captured Diagnostic Costs (Business Wire)
- FITs Offer Lowest Environmental Footprint Among CRC Screening Options (AJMC)
